相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Srdan Verstovsek et al.
LANCET (2023)
Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan
Ming-Chung Kuo et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
Ayalew Tefferi et al.
HAEMATOLOGICA (2023)
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach COMMENT
Daniel A. Arber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Improved survival of patients with myelofibrosis in the last decade: Single-center experience
Lucia Masarova et al.
CANCER (2022)
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Nico Gagelmann et al.
HAEMATOLOGICA (2022)
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
Paola Guglielmelli et al.
BLOOD ADVANCES (2022)
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
Srdan Verstovsek et al.
HAEMATOLOGICA (2022)
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
Monia Marchetti et al.
Lancet Haematology (2022)
The odyssey of pacritinib in myelofibrosis
Sangeetha Venugopal et al.
BLOOD ADVANCES (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Ruben Mesa et al.
LEUKEMIA (2022)
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib
Chandan Saha et al.
EXPERT REVIEW OF HEMATOLOGY (2022)
Myeloproliferative Neoplasms, Version 3.2022
Aaron T. Gerds et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Moshe Talpaz et al.
LEUKEMIA (2021)
Development of luspatercept to treat ineffective erythropoiesis
Anne Sophie Kubasch et al.
BLOOD ADVANCES (2021)
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis
Animesh Pardanani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
Alberto Alvarez-Larrán et al.
Lancet Haematology (2021)
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N. Harrison et al.
HEMASPHERE (2021)
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N. Harrison et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Massimo Breccia et al.
ANNALS OF HEMATOLOGY (2020)
The role of a low erythropoietin level for the polycythemia vera diagnosis
Oleksandra Lupak et al.
BLOOD CELLS MOLECULES AND DISEASES (2020)
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Francesca Palandri et al.
CANCER (2020)
The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication
Bridget K. Marcellino et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
The Myeloproliferative Neoplasm Landscape: A Patient's Eye View
Cheryl Petruk et al.
ADVANCES IN THERAPY (2020)
Management of myelofibrosis after ruxolitinib failure
Claire N. Harrison et al.
ANNALS OF HEMATOLOGY (2020)
How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy
Susan E. Robinson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications
Alessandra Malato et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the Ph1-negative Myeloproliferative Neoplasms Latium Group
Maria Gabriella Mazzucconi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
Dok Hyun Yoon et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Thrombocytosis and Thrombosis: Is There Really a Correlation?
Carlos Galvez et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria
Mohamed A. Yassin et al.
CANCER MEDICINE (2020)
Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Salvatrice Mancuso et al.
ONCOLOGY RESEARCH AND TREATMENT (2020)
Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review
Alessandra Malato et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
Joan How et al.
CANCERS (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
Yu-Hung Wang et al.
BLOOD CANCER JOURNAL (2020)
Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
Yizhou Peng et al.
INFECTION AND DRUG RESISTANCE (2020)
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Stephen T. Oh et al.
BLOOD ADVANCES (2020)
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Aaron T. Gerds et al.
BLOOD ADVANCES (2020)
Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
Vikas Gupta et al.
JCO ONCOLOGY PRACTICE (2020)
TO THE EDITOR: Guidance on changing therapy choice in myelofibrosis COMMENT
Donal P. McLornan et al.
BLOOD ADVANCES (2020)
Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting
Harinder Gill et al.
HEMATOLOGY (2020)
Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment
Harinder Gill et al.
ANNALS OF HEMATOLOGY (2019)
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study
Vikas Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis
T. Demuynck et al.
ANNALS OF HEMATOLOGY (2019)
Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy
Naveen Pemmaraju et al.
BLOOD (2019)
Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
Nico Gagelmann et al.
BLOOD (2019)
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Donal P. McLornan et al.
HAEMATOLOGICA (2019)
Stem cell transplant in MF: it's time to personalize
Francesco Passamonti
BLOOD (2019)
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naive essential thrombocythemia patients in a real-world setting
Tomoki Ito et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
Alberto Ferrari et al.
HAEMATOLOGICA (2019)
Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
Alessandra Iurlo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Abdulraheem Yacoub et al.
BLOOD (2019)
Momelotinib for the treatment of myelofibrosis
Li Xu et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
Lucia Masarova et al.
BLOOD (2019)
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis
Harinder Gill et al.
ANNALS OF HEMATOLOGY (2019)
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elena Maria Elli et al.
FRONTIERS IN ONCOLOGY (2019)
A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline
Mary Frances McMullin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms
Cecily J. Forsyth et al.
INTERNAL MEDICINE JOURNAL (2019)
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Jan Philipp Bewersdorf et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes
Danielle Cuthbert et al.
JOURNAL OF BLOOD MEDICINE (2019)
Updates in the management of polycythemia vera and essential thrombocythemia
Prithvirai Bose et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Primary myelofibrosis: spectrum of imaging features and disease-related complications
Sheng Fei Oon et al.
INSIGHTS INTO IMAGING (2019)
Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes A Systematic Review and Meta-analysis
Dawn Maze et al.
JAMA NETWORK OPEN (2019)
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
Gunnar Birgegard et al.
HAEMATOLOGICA (2018)
The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis
Ming-Chung Kuo et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
Gunnar Birgegard et al.
HAEMATOLOGICA (2018)
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
Martin Griesshammer et al.
ANNALS OF HEMATOLOGY (2018)
BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms
Qingfei Jiang et al.
CANCER CELL (2018)
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
Maria Kleppe et al.
CANCER CELL (2018)
Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia
Adolfo Enrique Diaz et al.
FUTURE ONCOLOGY (2018)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Pacritinib to treat myelofibrosis patients with thrombocytopenia
Douglas Tremblay et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
Natasha Szuber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masarova et al.
BLOOD (2018)
Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
Kamya Sankar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study
Gunnar Birgegard et al.
LEUKEMIA RESEARCH (2018)
Epidemiology of Patients with Classical Philadelphia-Chromosome Negative Myeloproliferative Neoplasms at a Single Academic Medical Center in Singapore
Priscella Shirley Chia et al.
BLOOD (2018)
Ruxolitinib-associated infections: A systematic review and meta-analysis
Federico Lussana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
Andrew T. Kuykendall et al.
ANNALS OF HEMATOLOGY (2018)
Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
Dilan Paranagama et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
Graeme Greenfield et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia
Yee Yee Yap et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013
Ja Min Byun et al.
ANNALS OF HEMATOLOGY (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Erhao Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
Ruben A. Mesa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
F. Passamonti et al.
LEUKEMIA (2017)
Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery
Sarah Chuzi et al.
LEUKEMIA & LYMPHOMA (2017)
Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome
Meera Yogarajah et al.
MAYO CLINIC PROCEEDINGS (2017)
Myeloproliferative Neoplasms
Jerry L. Spivak
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
How to define treatment failure for JAK inhibitors
Hans Michael Kvasnicka
LANCET HAEMATOLOGY (2017)
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa et al.
LANCET HAEMATOLOGY (2017)
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
Zimu Gong et al.
BLOOD ADVANCES (2017)
Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies
Leonard Naymagon et al.
HEMASPHERE (2017)
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
Lucia Masarova et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Kate J. Newberry et al.
BLOOD (2017)
Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
Georg Jeryczynski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli et al.
BLOOD (2017)
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Malte Asshoff et al.
BLOOD (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
Xenia Cabagnols et al.
BLOOD (2016)
Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes
Alberto Alvarez-Larran et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis
Harinder Gill et al.
HEMATOLOGY (2016)
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
H. Gisslinger et al.
LEUKEMIA (2016)
Laboratory Investigation of Myeloproliferative Neoplasms (MPNs)
Lambert Busque et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients
Mahnur Haider et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances
T. Barbui et al.
BLOOD REVIEWS (2016)
Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey
Ruben Mesa et al.
BMC CANCER (2016)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea
Yoojoo Lim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2016)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
C. N. Harrison et al.
LEUKEMIA (2016)
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
Gunnar Birgegard
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
Myelofibrosis: to transplant or not to transplant?
Rebecca Devlin et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review
Shreekant Parasuraman et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2016)
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
A. M. Vannucchi et al.
ANNALS OF ONCOLOGY (2015)
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Boonlerd Duangnapasatit et al.
Asian Pacific Journal of Cancer Prevention (2015)
White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
Tiziano Barbui et al.
BLOOD (2015)
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel et al.
BLOOD (2015)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
Heinz Gisslinger et al.
BLOOD (2015)
How we diagnose and treat essential thrombocythaemia
Samah Alimam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Adam J. Mead et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
A comprehensive review of pacritinib in myelofibrosis
Srdan Verstovsek et al.
FUTURE ONCOLOGY (2015)
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
Cecilia Arana Yi et al.
FUTURE ONCOLOGY (2015)
Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms
Y. R. Espasandin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
N. M. Kroeger et al.
LEUKEMIA (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Hans C. Hasselbalch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ruxolitinib for the treatment of patients with polycythemia vera
Jean-Jacques Kiladjian et al.
EXPERT REVIEW OF HEMATOLOGY (2015)
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
T. Barbui et al.
BLOOD CANCER JOURNAL (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
T. Barbui et al.
BLOOD CANCER JOURNAL (2015)
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Target hematologic values in the management of essential thrombocythemia and polycythemia vera
Juan Carlos Hernandez-Boluda et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms
Shuichi Shirane et al.
HAEMATOLOGICA (2015)
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
M. B. Agarwal et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2015)
Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
Alberto Alvarez-Larran et al.
ANNALS OF HEMATOLOGY (2014)
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno et al.
BLOOD (2014)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi et al.
BLOOD (2014)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Tiziano Barbui et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
Mario Cazzola et al.
BLOOD (2014)
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning
M. Shanavas et al.
BONE MARROW TRANSPLANTATION (2014)
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
John T. Reilly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera
Federico Lussana et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Myeloproliferative Disorders
Brian Meier et al.
EMERGENCY MEDICINE CLINICS OF NORTH AMERICA (2014)
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
Odile Moulard et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
Hajnalka Andrikovics et al.
HAEMATOLOGICA (2014)
Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials
John Mascarenhas et al.
HAEMATOLOGICA (2014)
Clinicopathologic characteristics of prefibrotic-early primary myelofibrosis in Chinese patients
Xubo Gong et al.
HUMAN PATHOLOGY (2014)
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
Zhiyuan Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment
R. Fu et al.
LEUKEMIA (2014)
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
A. Tefferi et al.
LEUKEMIA (2014)
Epidemiology of myeloproliferative neoplasms in the United States
Jyotsna Mehta et al.
LEUKEMIA & LYMPHOMA (2014)
Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients
Fabian P. Siegel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
Alfonso Quintas-Cardama et al.
BLOOD (2013)
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Emil T. Kuriakose et al.
HAEMATOLOGICA (2013)
Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up
Elisabeth Ejerblad et al.
HEMATOLOGY (2013)
Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines
Daryl Tan et al.
LANCET ONCOLOGY (2013)
Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013
Allen E. J. Yeoh et al.
LANCET ONCOLOGY (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study
Carlos Besses et al.
LEUKEMIA RESEARCH (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hepatic Manifestations in Hematological Disorders
Jun Murakami et al.
INTERNATIONAL JOURNAL OF HEPATOLOGY (2013)
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
Elisabetta Antonioli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Guideline for the diagnosis and management of myelofibrosis
John T. Reilly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Allogeneic transplantation: peripheral blood vs. bone marrow
William I. Bensinger
CURRENT OPINION IN ONCOLOGY (2012)
Incidence, survival and prevalence of myeloid malignancies in Europe
O. Visser et al.
EUROPEAN JOURNAL OF CANCER (2012)
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
Juergen Thiele et al.
BLOOD (2011)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Robyn Scherber et al.
BLOOD (2011)
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
Chiara Elena et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
D. Caramazza et al.
LEUKEMIA (2011)
Special Issues in Myeloproliferative Neoplasms
Tiziano Barbui et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2011)
High Percentage of JAK2 Exon 12 Mutation in Asian Patients With Polycythemia Vera
Yu-Min Yeh et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
Kebede Hussein et al.
BLOOD (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
Mrinal M. Patnaik et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kroeger et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
AML transformation in 56 patients with Ph- MPD in two well defined populations
Khadija Abdulkarim et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The natural history and treatment outcome of blast phase BCR-ABL(-) myeloproliferative neoplasms
Constantine S. Tam et al.
BLOOD (2008)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
J-J Kiladjian et al.
LEUKEMIA (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) - An international internet-based survey of 1179 MPD patients
Ruben A. Mesa et al.
CANCER (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycytheinia (ECLAP)
G Finazzi
PATHOLOGIE BIOLOGIE (2004)
Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia
M Messinezy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
分享论文
